Stock Performance and Market Context
On 20 July 2026, Gaudium IVF and Women Health Ltd recorded its highest-ever share price at Rs.144, surpassing previous levels and setting a new benchmark for the company. Despite a day’s decline of 2.72%, the stock remains well above its key moving averages, trading higher than the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust underlying trend.
In comparison, the Sensex declined by 0.77% on the same day, indicating that Gaudium IVF’s performance, while slightly weaker on the day, has outpaced the broader market over longer periods. The stock’s intraday low was Rs.136.55, representing a 4.88% dip from the day’s high, yet it closed near its peak levels, underscoring resilience amid short-term volatility.
Recent Trend and Relative Strength
The stock has experienced a mild reversal after two consecutive days of gains, yet its weekly and monthly performances remain impressive. Over the past week, Gaudium IVF advanced by 8.00%, significantly outperforming the Sensex’s marginal decline of 0.09%. The one-month gain stands at 28.47%, dwarfing the Sensex’s 0.97% rise, while the three-month performance is even more striking at 45.54%, compared to the Sensex’s 1.24% fall.
These figures highlight the stock’s strong momentum within the healthcare services sector, reflecting investor confidence in the company’s operational and financial metrics. The stock’s year-to-date and one-year performances are flat at 0.00%, contrasting with the Sensex’s declines of 9.00% and 5.15% respectively, indicating stability in a challenging market environment.
Valuation Metrics and Financial Ratios
At the current price of Rs.139.65 (as of 09:34 AM on 20 July 2026), Gaudium IVF trades at a price-to-earnings (P/E) ratio of 38 times trailing twelve months (TTM) earnings. The price-to-book value (P/BV) stands at 6.86 times, while the enterprise value to EBITDA (EV/EBITDA) ratio is 28.13 times. These multiples suggest a premium valuation consistent with the company’s growth profile and sector positioning.
The enterprise value to EBIT ratio is 30.17 times, and EV to sales is 10.16 times, reflecting the market’s recognition of the company’s earnings quality and revenue generation capabilities. The EV to capital employed ratio is 6.31 times, indicating efficient utilisation of capital resources. Dividend metrics are not applicable as the company has not declared dividends recently.
Technical Analysis and Trend Assessment
The overall technical trend for Gaudium IVF is mildly bullish, with the trend reversal occurring on 14 July 2026 at a price of Rs.134.95. Key technical indicators support this positive outlook: Bollinger Bands and Dow Theory signals are bullish, while the On-Balance Volume (OBV) indicator shows strength on both weekly and monthly timeframes. The Relative Strength Index (RSI) currently shows no signal, suggesting room for further price movement without being overbought.
Immediate support is established at the 52-week low of Rs.69.50, while the immediate resistance was previously noted near Rs.119.95, corresponding to the 20-day moving average. The stock has decisively surpassed these levels, now challenging the 52-week high of Rs.144, which represents a far resistance point.
Delivery Volumes and Market Participation
Delivery volumes have shown a positive trend, with a 34.8% increase over the past month and a 2.27% rise on the most recent trading day compared to the five-day average. On 17 July 2026, the stock recorded a delivery volume of 53.87 thousand shares, accounting for 11.58% of total volume, slightly below the five-day average of 11.77%. This steady participation indicates sustained investor interest and liquidity in the stock.
Quality Assessment and Financial Strength
Gaudium IVF’s overall quality grade reflects a solid financial foundation. The company exhibits good growth characteristics, with a strong average return on capital employed (ROCE) of 20.92%, signalling efficient capital utilisation. Its capital structure is excellent, supported by low leverage metrics: average debt to EBITDA stands at 0.65, and net debt to equity is effectively zero, indicating minimal financial risk.
Management risk is assessed as average, while growth prospects remain good. The company maintains a strong balance sheet with no promoter share pledging and low institutional holdings at 5.24%. Sales to capital employed ratio is 0.59x, and the tax ratio is 23.94%, consistent with industry norms. The average EBIT to interest coverage ratio of 14.59x demonstrates adequate ability to service debt obligations.
Financial Trend and Recent Quarterly Performance
Short-term financial trends as of March 2026 are flat, yet key quarterly metrics reveal positive momentum. The company’s profit after tax (PAT) for the quarter stood at ₹7.73 crores, growing at 42.0% compared to the previous four-quarter average. Net sales reached ₹22.17 crores, up 30.6%, while profit before tax excluding other income was ₹9.41 crores, increasing by 31.8%. These figures underscore the company’s ability to expand its top and bottom lines effectively.
Historical Price Range and Market Capitalisation
The stock’s 52-week price range spans from a low of Rs.69.50 to the new high of Rs.144.00, representing a remarkable 100.94% increase from the low point. The current price is just 3.02% below the all-time high, indicating proximity to peak valuation levels. Gaudium IVF is classified as a small-cap company, reflecting its market capitalisation relative to larger peers in the healthcare services sector.
Summary of Market Rating and Outlook
MarketsMOJO has upgraded the stock’s mojo grade from Sell to Hold as of 14 July 2026, with a current mojo score of 51.0. This rating reflects a balanced view of the company’s valuation and quality metrics, acknowledging recent gains while maintaining a cautious stance on further upside potential. The stock’s performance relative to sector and benchmark indices highlights its resilience and capacity to deliver value within its segment.
